Floatz logo

Pacritinib

Lymphoplasmacytic Lymphoma

Shayna Sarosiek, MDSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

43 Active assets in the Lymphoplasmacytic Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 3BB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Bendamustine
City of Hope Medical Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Pacritinib is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
chronic myelomonocytic leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →